


## PHARMACEUTICAL 2021



## NextCure Inc. Rank 48 of 409







## PHARMACEUTICAL 2021



## NextCure Inc. Rank 48 of 409



The relative strengths and weaknesses of NextCure Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of NextCure Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 106% points. The greatest weakness of NextCure Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 21% points.

The company's Economic Capital Ratio, given in the ranking table, is 110%, being 465% points above the market average of -355%.

Input Variable	Value in 1000 USD
Assets, Current	287,978
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	10,325
Liabilities, Non-Current	1,806
Other Assets	2,857
Other Compr. Net Income	779
Other Expenses	0
Other Liabilities	792
Other Net Income	4,622
Property and Equipment	15,809
Research and Development	46,554
Revenues	22,378
Selling, General and Administrative Expense	17,049

Output Variable	Value in 1000 USD
Assets	306,644
Liabilities	12,923
Expenses	63,603
Stockholders Equity	293,721
Net Income	-36,603
Comprehensive Net Income	-36,214
Economic Capital Ratio	110%

